IGFs and human cancer: Implications regarding the risk of growth hormone therapy

Hormone Research

Volumn 51, Issue SUPPL. 3, 1999, Pages 42-51

  Shim, Melanie ^a   Cohen, Pinchas ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Breast cancer; Growth hormone; Insulin like growth factor; Insulin like growth factor binding protein; Lung cancer; Malignancy; Prostate cancer

Indexed keywords

CATHEPSIN D; GROWTH HORMONE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; APOPTOSIS; BLOOD LEVEL; BREAST CANCER; CANCER; CANCER CELL; CANCER MORTALITY; CANCER RISK; COLON CANCER; CONFERENCE PAPER; GROWTH HORMONE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; LUNG CANCER; MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN SYNTHESIS;

EID: 0032696744     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053161     Document Type: Conference Paper

References (91)

1. Ray D, Melmed S: Pituitary cytokine and growth factor expression and action. Endocr Rev 1997;18:206-228.
2. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801-831.
3. Kurland ES, Chan FKW, Rosen C, Bilezikian JP: Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1998;83: 2576-2579.
4. Sussenbach JS, Steenbergh PH, Holthuizen P: Structure and expression of the human insulin-like growth factor genes. Growth Regul 1992;2: 1-9.
5. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P: Insulin-like growth factor binding protein (IGFBP) proteases; functional regulators of cell growth. Prog Growth Factor Res 1995;6:273-284.
6. Macauly VM: Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-320.
7. 2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56:1545-1550.
8. Werner H, Karnieli E, Rauscher FJ, LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996;93:8318-8323.
9. Grimberg A, Rajah R, Zhao H, Cohen P: The prostatic IGF system: new levels of complexity; in Takano K, Hizuka N, Takahashi SI (eds): Molecular Mechanisms to Regulate the Activities of Insulin-like Growth Factors. Amsterdam, Elsevier, 1998, pp 205-215.
10. Cohen P, Peehl DM, Bhala A, Dong G, Hintz RL, Rosenfeld RG: The IGF axis in prostatic disease; in Baxter RC, Gluckman PD, Rosenfeld RG (eds): The IGFs and Their Regulatory Proteins. Amsterdam, Elsevier, 1994, p. 369.
11. Cohen P, Peehl DM, Lamson G, Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-407.
12. Cohen P, Peehl DM, Marker B, Liu F, Hintz RL, Rosenfeld RG: Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410-1414.
13. Angelloz-Nicoud P, Binoux M: Autocrine regulation of cell proliferation by the insulin-like growth factor(IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinol 1995;136:5485-5492.
14. Figueroa JA, Lee AV, Jackson JG, Yee D: Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-I: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 1995;80:3476-3482.
15. Plymate SR, Tennant M, Birnbaum RS, Thrasher JB, Chatta G, Ware JL: The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab 1996;81:3709-3716.
16. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birngaum RS, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGFII mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-3782.
17. Wang YZ, Wong YC: Sex hormone-induced prostatic carcinogenesis in the Noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998;35:165-177.
18. Nickerson T, Pollak M, Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4, and 5. Endocrinology 1998; 139:807-831.
19. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld PG: Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-1035.
20. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M: Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 1998;159:2220-2225.
21. Cohen P, Peehl DM, Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 1994;26: 81-84.
22. 1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.
23. Nunn SE, Gibson TB, Rajah R, Cohen P: Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases. Endocrine 1997;7:115-118.
24. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75: 1046-1053.
25. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG: Biological effects of prostate specific antigen (PSA) as an IGFBP-3 protease. J Endocrinol 1994;142:407-411.
26. Nunn SE, Peehl DM, Cohen P: Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 1997;171:196-200.
27. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor binding protein-2 is increased and IGFBP3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-233.
28. Stamey TA, Kabalin JN, McNeil JE, Johnstone IM, Freiha F, Redwine EA, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. J Urol 1989;141:1076.
29. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566.
30. Wolk A, Mantzoros CS, Andersson S-O, Bergstrom R, Signorello LB, Lagiou P, Adami H-O, Dimitrios R: Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-915.
31. Oh Y: IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 1998;47:283-293.
32. Yee D, Paik S, Levovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-517.
33. Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 1988;48: 6691-6696.
34. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995;49: 415-421.
35. Lee AV, Weng C-N, Jackson JG, Yee D: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47.
36. Peyrat JP, Bonneteterre H, Vennin PH, Jammes J, Beuscart R, Hecquet B, Djiane J, Lefebvre J, Demaille A: Insulin-like growth factor I receptors and IGF I in human breast tumors. J Steroid Biochem Mol Biol 1990;37: 823-827.
37. Pollak MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I. Breast Cancer Res Treat 1992;128:1115-1122.
38. Colleti RB, Robers JD, Devlin JT, Copeland KC: Effect of tamoxifen on plasma insulin like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882-1884.
39. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L: Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998;46:255-267.
40. Pezzino V, Papa V, Milazzo G, Gliozzzo B, Russo P, Scalia PL: Insulin-like growth factor-I receptors in breast cancer. Ann N Y Acad Sci 1996;784:189-201.
41. Arteaga C: Interference of the IGF-I system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 1992;22:101-106.
42. Brunner N, Spang-Thomsen M, Cullen K: The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 1996;39:87-92.
43. Stewart A, Johnson MD, May FEB, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265: 21172-21178.
44. Kawamura I, Lacey E, Mizota T, Tsujimoto S, Nishigaki F, Manda T, Shimomura K: The effect of droloxifene on the insulin-like growth factor-I stimulated growth of breast cancer cells. Anticancer Res 1994;14:427-432.
45. Oh YM, Muller HL, Lamson G, Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells - cell surface binding and growth inhibition. J Biol Chem 1993;268: 14964-14971.
46. Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT, Fontana JA: Insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 1994;158: 69-78.
47. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Dimandi A, Clark GM, Diamandis EP: Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer 1998; 79;624-628.
48. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C, Lee AV, Yee D: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997;3:103-109.
49. Schmitt M, Goretzki L, Janicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H: Biological and clinical relevance of the urokinase-type plasminogen activator in breast cancer. Biomed Biochim Acta 1991;50: 731-741.
50. Conover CA, De Leon DD: Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells: role of cathepsin D. J Biol Chem 1994;269:7076-7080.
51. Yu H, Diamandis EP, Sutherland DJA: Immunoreactive prostate-specific antigens levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-79.
52. Salahifar H, Baxter RC, Martin JL: Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology 1997; 138: 1683-1690.
53. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
54. Favoni RE, De Cupis A, Ravera F, Cantoni C, Pirani P, Adreizzoni A, Noonan D, Biassoni R: Expression and function of the insulin like growth factor I system in human non small cell lung cancer and normal lung cell lines. Int J Cancer 1994;56:858-866.
55. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshin JL, Cuttitta F: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996;271:11477-11483.
56. Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, Havemann K: Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 1997;138:17657-17670.
57. Noll K, Wegmann BR, Havemann K, Jaques G: Insulin-like growth factors stimulate the release of insulin-like growth factor binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in non small cell lung cancer cell lines. J Clin Endocrinol Metab 1996;81:2653-2662.
58. Ankrapp DP, Bevan DR: Insulin-like growth factor-I and human lung fibroblast-derived insulin-like growth factor-I stimulates the proliferation of human lung carcinoma in vitro. Cancer Res 1993;53:3399-3404.
59. Enoch T, Nurse P: Coupling M phase and S phase: controls maintaining the dependence of mitosis on chromosome replication. Cell 1991; 65:921-923.
60. Reeve JG, Brinkman A, Hughes S, Mitchell J, Schwander J, Blechen NM: Expression of insulin-like growth factor (IGF) and IGF-I binding proteins genes in human lung tumor cell lines. J Natl Cancer Inst 1992;84:628-634.
61. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K: Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 1993;119:665-668.
62. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-156.
63. Moon HD, Li CH, Simpson ME: Effect of pituitary hormones on carcinogenesis with 9,10-dimethyl-1,2-dibenzanthracene in hypophysectomized rats. Cancer Res 1956;16:111-116.
64. Bently HB, Hughes ER, Peterson RDA: Effect of hypophysectomy on a virus-induced T-cell leukemia. Nature 1974;252:747-748.
65. Moon HD, Simpson ME, Li CH, Evans HM: Neoplasms in rats with pituitary growth hormone: pulmonary and lymphatic tissues. Cancer Res 1950;10:297-308.
66. Shalet SM, Brennan BM, Reddingius RE: Growth hormone therapy and malignancy. Horm Res 1997;48(suppl 4):29-32.
67. Blatt J, Wenger S, Stitely S, Lee PA: Lack of mitogenic effects of growth hormone on human leukemic lymphoblasts. Eur J Pediatr 1987; 146:257-260.
68. Estrov Z, Meir R, Barak Y, Zaisov R, Zadik Z: Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic cells. J Clin Oncol 1991;9: 394-399.
69. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA: Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997;3:1141-1144.
70. Sinha YN, Vlahakis G, Vanderlaan WP: Serum, pituitary, and urine concentrations of prolactin and growth hormone in eight strains of mice with varying incidence of mammary tumors. Int J Cancer 1979;24:430-437.
71. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P: Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 1997;75:1585-1592.
72. Lamharzi N, Schally AV, Koppan M, Groot K: Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-II in tumors. Proc Natl Acad Sci USA 1998; 95:8864-8868.
73. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson OGP: High frequency of mammary adenocarcinomas in metallothioneine promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 1992;42: 237-242.
74. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaaksson O, Tornell J: Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744-2751.
75. Bengtsson B-Å: Acromegaly and neoplasia. J Pediatr Endocrinol 1993;6:73-76.
76. Ezzat S, Melmed S: Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991;72: 245-249.
77. Ezzat S, Carey S, Melmed S: Colon polyps in acromegaly. J Clin Endocrinol Metab 1991;72: 245-249.
78. Colao A, Balzano A, Ferone D, Panza N, Grande G, Marzullo P, Bove A, Iodice G, Merola B, Lombardi G: Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) 1997;47: 23-28.
79. Barxilay J, Heatley GJ, Cushin GW: Benign and malignant tumors in patients with acromegaly. Arch Intern Med 1991;151:1629.
80. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr: Acromegaly and gastrointestinal cancer. Cancer 1991;58:1673 [erratum in Cancer 1992;69:549].
81. Ladas SD, Thalassinos NC, Toannides G, Raptis SA: Does acromegaly really predispose to an increased prevalence of gastrointestinal tumors? Clin Endocrinol (Oxf) 1994;41:597-601.
82. Klein I, Parveen G, Gavoeler JS, Vanthiel DH: Colonic polyps in patients with acromegaly. Ann Intern Med 1982;97:27-30.
83. Colao A, Marzullo P, Ferone D, Spieza S, Cerbone G, Marino V, Di Sarno A, Merola B, Lombardi G: Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998;83:775-779.
84. Cohen P: Serum insulin-like growth factor-I levels and prostate cancer risk - interpreting the evidence. J Natl Cancer Inst 1998;90:876-879.
85. Watanabe S, Tsunematus Y, Fujimoto J: Leukaemia in patients treated with growth hormone. Lancet 1988;21:1159-1162.
86. Blethen SL: Complications of growth hormone therapy in children. Curr Opin Pediatr 1995;7: 466-471.
87. Allen DB: Safety of human growth hormone therapy: current topics. J Pediatr 1996;128:S8.
88. Tuffli GA, Johanson A, Rundle AC, Allen DB: Lack of increased risk for extracranial nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 1995;80:1416-1422.
89. Rosén T, Bengtsson B-Å: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-288.
90. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-2734.
91. Petridou E, Dessypros N, Spanos E, Mantzoros C, Skalkidou A, Kalmanti M, Koliouskas D, Kosmidis H, Panagiotou JP, Piperopoulou F, Tzortzatou F, Trichopoulos D: Insulin-like growth factor-I and binding protein-3 in relation to childhood leukemia. Int J Cancer 1999; 80:494-496.